The FDA approved Travere's drug for the kidney disease FSGS based on the surrogate endpoint of proteinuria, despite the drug failing on the traditional eGFR endpoint. This decision, following a company-backed effort to validate proteinuria, suggests increased regulatory flexibility and creates a new pathway for kidney disease drug approvals.

Unlike typical safety-focused Phase 1 trials, Jade's trial for IgA nephropathy in healthy volunteers provides highly translatable efficacy data. Measuring the drop in IgA, a key biomarker, in healthy subjects directly predicts the drug's clinical activity in patients, significantly de-risking later-stage development before treating a single patient.

Recent clinical trial data showing that liver fibrosis in MASH can be reversed has re-energized the entire fibrosis therapeutic area. This progress provides a crucial proof-of-concept that halting or even reversing fibrotic damage may be achievable in other organs, such as the lungs in IPF.

Running an unusually long, two-year Phase 2 trial allowed Vera to demonstrate stabilization of GFR, a hard kidney function endpoint. This robust, long-term data was crucial for de-risking their Phase 3 program and ultimately securing a coveted Breakthrough Therapy Designation from the FDA, accelerating their path to market.

The company's confidence in aiming for a cure is supported by real-world evidence. Patients with autoimmune diseases who receive bone marrow transplants for cancer are often incidentally cured of their autoimmunity due to the new immune system's different HLA profile. Rumagen aims to replicate this outcome safely with an autologous approach.

The drug's mechanism avoids maximum suppression, instead aiming for a precise balance—"not too much, not too little." This "Goldilocks" approach to intercepting BAF and APRIL cytokines is key to resolving inflammation and stabilizing kidney function without causing excessive immunosuppression, a critical differentiator in autoimmune therapies.

Coya Therapeutics' vision is to make diseases like ALS "livable" by completely stopping their progression. This ambitious goal stems from a small investigator-initiated trial where patients showed no disease progression over six months, a period where a significant decline is typically expected, reframing the therapeutic benchmark.

Of the 30+ million Americans with chronic kidney disease (CKD), most are unaware they have it. The greatest societal impact would come not from a new therapy, but from widespread screening and education, as existing drugs and lifestyle changes can help patients in the early stages before they need advanced care.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.